DEFY Blogsearch the defy medical knowledge base:
Sermorelin Acetate for Injection (GHRH)
Sermorelin Acetate is compounded in the following strength: 15mg (15,000 micrograms).
Mix the Bacteriostatic water provided into the vial of Sermorelin using a large “mixing syringe” with attached needle. This is done by using the mixing syringe to draw the appropriate amount of bacteriostatic water and dispensing it into the vial of Sermorelin. Usually the mixing syringe is between 3ML and 10ML in size (not to be confused with the much smaller syringes used to inject). For 15mg vial of Sermorelin: Using the mixing syringe, dilute (mix) 7.5ml of bacteriostatic water.
Next, Swirl the vial with a gentle rotary motion until contents are dissolved- DO NOT SHAK
Now you are ready to administer your Sermorelin. Please note that 10 units on the syringe = 200mcg of Sermorelin when measured on the syringe used to inject, usually an “insulin” syringe. This is indicated in the diagram below. So if your prescribe dose is 1000mcg this means you draw to the 50 unit mark on the syringe.
You may use this mixture for up to 90 days, but remember to keep it refrigerated after mixing. If you accidentally leave your sermorelin out of the fridge don’t worry, sermorelin can be left at room temperature for 72 hours after being mixed.
Be sure to properly dispose of all syringes and needles after use.
This diagram shows a ½ cc Insulin syringe which contains up to 50 units. Please note there are different sizes of syringes, including 1cc (100unit) syringes. The amount you are instructed to draw to will remain consistent no matter the syringe size.
[Sermorelin Acetate for Injection]
15mg (15,000mcg per vial): Individual pharmacies may offer different strengths.
* Always be sure to check the label to confirm that you have received the correct strength
The diluent is Bacteriostatic Water for Injection, USP containing 0.9% Benzyl Alcohol added as an antimicrobial preservative. Do not use any other diluent unless approved by the prescribing physician. Refrigerate after reconstitution.
BEFORE USING THIS MEDICINE:
Inform your Doctor or Pharmacist if you are allergic to any prescription or non-prescription medicine; taking other medicines or have other medical problems; pregnant, planning a pregnancy, or breast feeding.
Check with your Doctor, Pharmacists, or Nurse if information in this leaflet causes you special concern or if you want additional information about your medicine and its use.
COMMON USES FOR THIS MEDICINE:
For replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria:
Adult Onset: Patients who have growth hormone deficiency either alone, or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma.
Childhood Onset: Patients who were growth hormone deficient during childhood who have growth hormone deficiency confirmed as an adult before replacement therapy is started.
HOW TO USE THIS MEDICINE:
Use this medicine exactly as directed on the label, unless instructed differently by your doctor
* DO NOT inject if solution is cloudy or contains particles. Contact your doctor or pharmacy
WHAT TO DO IF YOU MISS A DOSE: Take when remembered unless time for next dose. No double doses.
HOW TO STORE THIS MEDICINE: Refrigerate in original container away from children. Do not freeze. Discard unneeded medicine.
ADVERSE REACTIONS: The following adverse reaction, in decreasing order of frequency, have been reported following sermorelin administration:
Approximately one in four patients given repeated doses of one or more of the three forms of GRH (1-29, 1-40, and 1-44) has developed antibodies to GRH. The clinical significance of these antibodies is unknown. One patient who developed antibodies to GRH (1-44) also experienced an allergic reaction described as severe redness, swelling, and urticaria at the injection sites. No long-lasting effects from this reaction were reported. No symptomatic allergic reactions to GRH (1-29) have been reported.